SCS Stock Overview
Operates as a biotechnology company in Poland. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Stem Cells Spin S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | zł0.19 |
| 52 Week High | zł0.81 |
| 52 Week Low | zł0.17 |
| Beta | 0.89 |
| 1 Month Change | -17.83% |
| 3 Month Change | -9.13% |
| 1 Year Change | -48.64% |
| 3 Year Change | -65.64% |
| 5 Year Change | -65.64% |
| Change since IPO | -91.60% |
Recent News & Updates
Recent updates
Shareholder Returns
| SCS | PL Biotechs | PL Market | |
|---|---|---|---|
| 7D | -5.5% | -3.4% | -2.6% |
| 1Y | -48.6% | -25.9% | -4.9% |
Return vs Industry: SCS underperformed the Polish Biotechs industry which returned -25.9% over the past year.
Return vs Market: SCS underperformed the Polish Market which returned -4.9% over the past year.
Price Volatility
| SCS volatility | |
|---|---|
| SCS Average Weekly Movement | 11.2% |
| Biotechs Industry Average Movement | 5.9% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in PL Market | 8.7% |
| 10% least volatile stocks in PL Market | 3.2% |
Stable Share Price: SCS's share price has been volatile over the past 3 months compared to the Polish market.
Volatility Over Time: SCS's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of Polish stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2009 | 1 | Adam Symber | stemcellsspin.com.pl |
Stem Cells Spin S.A. operates as a biotechnology company in Poland. It engages in the development, cultivation, and application of stem cells using MIC-1 stem cells for human and veterinary medicine, and dermocosmetics applications. The company offers biodermocosmetics under the Revitacell brand name.
Stem Cells Spin S.A. Fundamentals Summary
| SCS fundamental statistics | |
|---|---|
| Market cap | zł7.81m |
| Earnings (TTM) | -zł353.29k |
| Revenue (TTM) | zł223.67k |
34.9x
P/S Ratio-22.1x
P/E RatioIs SCS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SCS income statement (TTM) | |
|---|---|
| Revenue | zł223.67k |
| Cost of Revenue | zł44.14k |
| Gross Profit | zł179.53k |
| Other Expenses | zł532.82k |
| Earnings | -zł353.29k |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.0085 |
| Gross Margin | 80.27% |
| Net Profit Margin | -157.95% |
| Debt/Equity Ratio | 0.7% |
How did SCS perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/22 09:27 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Stem Cells Spin S.A. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|